key: cord-0693027-p0w10tpy authors: Mahan, Luke D.; Lill, Isaac; Halverson, Quinn; Mohanka, Manish R.; Lawrence, Adrian; Joerns, John; Bollineni, Srinivas; Kaza, Vaidehi; La Hoz, Ricardo M.; Zhang, Song; Kershaw, Corey D.; Terada, Lance S.; Torres, Fernando; Banga, Amit title: Post‐infection pulmonary sequelae after COVID‐19 among patients with lung transplantation date: 2021-10-17 journal: Transpl Infect Dis DOI: 10.1111/tid.13739 sha: 1d92d2a2d050abcf5e07b158112e2f47a4539fde doc_id: 693027 cord_uid: p0w10tpy BACKGROUND: There is limited data on outcomes among lung transplant (LT) patients who survive Coronavirus disease 2019 (COVID‐19). METHODS: Any single or bilateral LT patients who tested positive for SARS‐CoV‐2 between March 1, 2020, to February 15, 2021 (n = 54) and survived the acute illness were included (final n = 44). Each patient completed at least 3 months of follow‐up (median: 4.5; range 3–12 months) after their index hospitalization for COVID‐19. The primary endpoint was a significant loss of lung functions (defined as > 10% decline in forced vital capacity (FVC) or forced expiratory volume in 1 s (FEV(1)) on two spirometries, at least 3 weeks apart compared to the pre‐infection baseline). RESULTS: A majority of the COVID‐19 survivors had persistent parenchymal opacities (n = 29, 65.9%) on post‐infection CT chest. Patients had significantly impaired functional status, with the majority reporting residual disabilities (Karnofsky performance scale score of 70% or worse; n = 32, 72.7%). A significant loss of lung function was observed among 18 patients (40.9%). Three patients met the criteria for new chronic lung allograft dysfunction (CLAD) following COVID‐19 (5.6%), with all three demonstrating restrictive allograft syndrome phenotype. An absolute lymphocyte count < 0.6 × 10(3)/dl and ferritin > 150 ng/ml at the time of hospital discharge was independently associated with significant lung function loss. CONCLUSIONS: A significant proportion of COVID‐19 survivors suffer persistent allograft injury. Low absolute lymphocyte counts (ALC) and elevated ferritin levels at the conclusion of the hospital course may provide useful prognostic information and form the basis of a customized strategy for ongoing monitoring and management of allograft dysfunction. TWEET: Twitter handle: @AmitBangaMD Lung transplant patients who survive COVID‐19 suffer significant morbidity with persistent pulmonary opacities, loss of lung functions, and functional deficits. Residual elevation of the inflammatory markers is predictive. The early impact of Coronavirus disease 2019 (COVID-19) among patients with lung transplantation (LT), including the significant inhospital morbidity and mortality, has now been reported by multiple groups across different countries. [1] [2] [3] [4] [5] Despite improved hospital survival in more recent studies, 1,3 LT patients with COVID-19 seem to be at an increased risk of severe diseases such as the development of respiratory failure and need for respiratory support strategies that require intensive care unit (ICU) admission. A more severe clinical course consisting of lower respiratory tract involvement with respiratory viral infections (RVI) has been reported to increase the risk of progressive allograft injury among LT patients. 6 The focus of a large majority of the current work has been the acute illness and its impact on the allograft, which by virtue of being the target of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is at a uniquely high risk of dysfunction compared to patients with other types of solid organ transplantation. However, there is limited data on outcomes among the patients who survive COVID-19. As a group, RVIs have been associated with post-infection allograft dysfunction among LT patients via activation of alloimmune pathways that increase the risk of chronic lung allograft dysfunction (CLAD). [7] [8] [9] Furthermore, previous research has demonstrated that acute illness from SARS-Cov-2 infection is more severe than a respiratory syncytial virus (RSV) in LT patients. 1 Apart from the direct injury to the allograft from the SARS-Cov-2 virus, the secondary damage from the activation of systemic inflammatory pathways, coagulation dysfunction, and immunothrombosis are all somewhat unique to COVID-19. 10, 11 Furthermore, COVID-19 has the potential for significant long-term effects even among non-transplant patients. 12 These considerations raise the concerns regarding the long-term implications of COVID-19 among LT patients and its impact on the allograft. Indeed, there are isolated reports of LT patients with COVID-19 experiencing accelerated progression to CLAD after recovering from acute infection. 13, 14 The current work reports the outcomes after COVID-19 among LT patients who survive acute illness, focusing on post-infection spirometry. We sought to determine the frequency of significant loss of lung functions assessed via spirometry among a cohort of COVID-19 survivors. In addition, we elucidated clinical predictors that could facilitate prognostication and permit consideration of customized management strategies during the acute infection with SARS-CoV-2. The current study was a single-center chart review study approved During the study period, 54 patients were diagnosed with COVID-19, the majority of which were hospitalized (n = 50, 92.6%). Among the four patients managed as outpatients, three were approved for bam- During the course of acute illness, parenchymal involvement was evident on chest radiographs among a majority of the study group (n = 27, The baseline characteristics of the patients with and without significant loss in FVC or FEV 1 after COVID-19 are compared in Table 1 . Although none of the comparisons achieved statistical significance, patients with restrictive lung disease appeared to be at a higher risk of significant loss in lung functions, while those with obstructive lung disease were at lower risk. In addition, although statistically not significant, patients with a lower reserve, as reflected by the lower median pre-infection FVC and FEV 1 , may be at a higher risk of post-COVID-19 lung function loss. They also appeared to have a more severe illness at presentation as reflected by a higher incidence of lower respiratory tract symptoms and spirometry decline at presentation, opacities on chest radiographs, and need for hospitalization. The laboratory variables during the course of acute illness are compared between the two groups in Table 1 While the pharmacotherapeutic strategies were similar among the two groups (Table 2) , patients with acute chronic respiratory failure appeared more likely to suffer loss in lung functions (p > 0.05). Although the need for ICU admission during the acute illness predicted subsequent lung function loss, the need for readmission and cumulative length of hospital stay were similar between the two groups. On multivariate logistic regression analysis, ALC < < 0.6 X10 3 /dl The current study reports the outcomes among a cohort of lung transplant patients who survived COVID-19. We focused on assessing the impact of COVID-19 on lung functions beyond acute illness. We found that a high proportion of COVID-19 survivors are left with structural abnormalities on their allografts and impairment in pulmonary physiology on spirometry. Furthermore, we identified two laboratory variables, ALC, and ferritin, during the index hospitalization that emerged as independent predictors of significant loss of lung functions. A small but significant proportion of patients met the criteria for new CLAD after COVID-19. All these patients were classified as RAS phenotype based on the restrictive pulmonary physiology and typical radiological changes. However, these radiological abnormalities were essentially indistinguishable from post-COVID opacities among other patients in the study group who did not meet the physiologic criteria. We defined the significant loss of lung functions as at least a 10% or more decline in either FVC or FEV 1 on post-infection spirometry on two or more occasions. This variable has been found to be a useful pre-dictor of adverse outcomes after RVI among LT patients, although it has not been studied among patients with COVID-19. 17, 18 In a large cohort of LT patients with RSV infection, an early decline in FEV 1 > 10% was noted among 13% of the patients and was an independent predictor of post-RSV mortality. 18 Similarly, our group found that more than a third of the LT patients suffered > 10% decline in FEV 1 or FVC during the 6 months after RSV infection and, along with pre-infection CLAD, was an independent predictor of mortality at one year after the RSV infection. although we did not find them to predict hospital outcomes among LT patients. 1 Similarly, none of the laboratory variables at presentation or during the hospital course were associated with the subsequent lung function loss in the current analysis. Instead, elevated ferritin and suppressed ALC at hospital discharge appeared to predict significant lung function loss. It is noteworthy that none of the 12 patients with ALC > 0.6 × 10 3 /dl and ferritin < 150 ng/ml at the time of hospital discharge suffered a significant loss in lung functions. This suggests that the severity of inflammatory response at the time of diagnosis or its peak during the course of acute illness may not be as consequential as the persistence of the inflammatory milieu among LT patients. The mechanisms for low ALC during COVID-19 are not well understood, although it is believed to be the effect of the cytokine storm from the active infection, mediated via the pro-inflammatory cytokines. 24 The association of low ALC with worse post-infection outcomes incriminates the acute infection, instead of the activation of alloimmune pathways, as the likely culprit for subsequent allograft dysfunction. The role of ferritin as a predictor of outcomes among patients with COVID-19 remains unclear. Studies from China found that ferritin levels were associated with disease severity, although it is unclear if it is a byproduct or a mediator of the cytokine storm. 23 Hyperferritinemia in COVID-19 has been likened to secondary hemophagocytic lymphohistiocytosis and is a key mediator of pulmonary fibrosis that can follow severe COVID-19. 25 Intriguingly, the extent of ferritin elevation has been found to predict the severity of lung involvement assessed via CT chest among patients with COVID-19. 26 Despite being the largest study to date reporting post-acute illness outcomes, the study was not powered to determine additional statistically significant associations with the endpoint. Additionally, the model could not be fitted with all potential confounders, and fully adjusted associations must await studies that include a larger sample size. Regardless, we did have additional clinically relevant variables in the multivariate model to adjust the associations for these variables apart from those significant on univariate analysis (at p-value < .1). Although we identified independent predictors of lung function loss among COVID-19 survivors and the associations do appear biologically plausible, causality cannot be determined and must await mechanistic studies in the future. It is concluded that a significant proportion of COVID-19 survivors suffer persistent allograft injury as reflected by the parenchymal opacities and loss of lung functions on spirometry. While post-viral activation of alloimmune pathways can contribute, the allograft injury from COVID-19 may be driven by the smoldering inflammation linked to the acute infection. A persistently low ALC and elevated ferritin at the conclusion of the hospital course may provide useful prognostic informa-tion and form the basis of a customized strategy for ongoing monitoring and management of allograft dysfunction. None. Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19 COVID-19 in lung transplant patients: a case series COVID-19 in lung transplant recipients: a multicenter study From the columbia university lung transplant program. COVID-19 in lung transplant recipients: a single center case series from New York City French group of lung transplantation. COVID-19 in lung transplant recipients Graft loss and CLAD-Onset is hastened by viral pneumonia after lung transplantation Symptomatic respiratory virus infection and chronic lung allograft dysfunction CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection-myth or reality? COVID-19-associated coagulopathy: an exploration of mechanisms Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Long covid-mechanisms, risk factors, and management COVID-19 in a lung transplant patient: rapid progressive chronic lung allograft dysfunction COVID-19 in a lung transplant recipient: exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression Standardization of spirometry, 1994 update Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the pulmonary council of the ISHLT Characteristics and outcomes among lung transplant patients with respiratory syncytial virus infection Oral and inhaled ribavirin treatment for respiratory syncytial virus infection in lung transplant recipients Impact of COVID-19 on lung allograft and clinical outcomes in lung transplant recipients: a case-control study Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis Hyperferritinemia in critically ill COVID-19 patients -Is ferritin the product of inflammation or a pathogenic mediator Lymphopenia during the COVID-19 infection: what it shows and what can be learned COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation The authors declare that they have no conflict of interest. Study design: Amit Banga; Data collection and management: Luke D.